Japanese Big Pharma Takeda and VC Lightstone have come together to launch Cerevance, a newco focused on neuroscience R&D for neurological and psychiatric…

After getting off its $100 million-plus IPO in the summer, gene editing biotech Intellia Therapeutics is getting ready for human tests of its preclinical…

Facebook and Napster billionaire Sean Parker has seen his Institute for Cancer Immunotherapy join forces with the Cancer Research Institute (CRI) to work on…

AstraZeneca has penned a pact to develop bicyclic peptides with Bicycle Therapeutics.

OncoMed has posted early data on two antibodies for cancer, but investors are still focused on prospects for cancer stem cell drug tarextumab.

Longwood Fund and Domain Associates have led a $19.15 million funding round for newco Axial Biotherapeutics with the aim of creating new treatments for an…

A few weeks back, and in fact the day before the U.S. election, RNAi biotech Arrowhead quietly posted some miserable news that its hep B candidate, ARC-520,…

Sanofi has assumed responsibility for Warp Drive Bio's aminoglycoside antibiotic program.

R&D